Question: Were the appropriate alternatives or comparators considered?
Answer Options:
A. No. There are many other relevant treatments for secondary prevention of MI that were not included.
B. No. The study did not compare other types of pharmacoeconomic analyses.
C. Yes. There were at least two comparisons and both were drugs that are commonly recommended by treatment guidelines.
D. Yes. There were two comparisons and each comparator represented a different class of drugs that is commonly used and clinically relevant.
Answer: D. Yes. There were two comparisons and each comparator represented a different class of drugs that is commonly used and clinically relevant.
Question: Best pharmacoeconomic study to compare these drugs with similar efficacy and side effect profiles?
Answer Options:
A. Cost-minimization
B. Cost-utility
C. Cost-of-illness
D. Cost-effectiveness
E. None of the above
Answer: A. Cost-minimization
Question: Conclusion from real-world study comparing cholestyramine vs simvastatin?
Answer Options:
A. Simvastatin demonstrated better effectiveness.
B. Simvastatin demonstrated better efficacy.
C. Simvastatin demonstrated comparable efficacy to cholestyramine.
D. Cholestyramine and simvastatin are equally cost-effective.
E. Simvastatin is more cost-effective than Cholestyramine.
Answer: E. Simvastatin is more cost-effective than Cholestyramine.
Question: What is the best type of pharmacoeconomic study to compare Firstatin and Secondstatin?
Answer Options:
A. Cost-minimization
B. Cost-utility
C. Cost-of-illness
D. Cost-effectiveness
E. None of the above
Answer: D. Cost-effectiveness
Question: Which drug is more cost-effective? (Firstatin vs Secondstatin, LDL reduced more by Secondstatin, lower cost)
Answer Options:
A. Firstatin costs more but results in better clinical outcomes, thus is more cost effective
B. Secondstatin dominates Firstatin. It is cheaper and more effective in reducing LDL.
C. Given different doses, the drugs cannot be compared
D. Firstatin is more cost effective
E. Drugs have same cost-effectiveness
Answer: B. Secondstatin dominates Firstatin. It is cheaper and more effective in reducing LDL.
Question: Is this new vaccine program cost-effective? (5 additional life years, $495,000 cost increase, λ = $60,000 per life year)
Answer Options:
A. Yes.
B. No.
C. We cannot determine unless we have the value of lambda (λ)
D. It depends on their willingness to pay for vaccination.
E. None of the above.
Answer: A. Yes.
Question: Which quadrant is the most cost-effective?
Answer Options:
A. Quadrant I
B. Quadrant II or IV
C. Quadrant III
D. Quadrant I or III
E. Quadrant IV
Answer: E. Quadrant IV
Question: What is the opportunity cost to St. Mary’s Hospital to provide hospital care to John for his heart attack?
Answer Options:
A. $108,000
B. $8,000
C. $100,000
D. $85,000
E. $75,000
Answer: D. $85,000
Question: Was adjustment or discounting appropriate/necessary? If so, was it conducted?
Answer Options:
A. No. Adjustment and discounting were not necessary because the study lasted only one year and they did not discuss using costs from the past or any events or costs that accrue in the future.
B. No. Adjustment and discounting were not appropriate because the authors used the Average Wholesale Price and the cost-to-charge ratio.
C. Yes. Adjustment and discounting were necessary but the authors did not conduct it.
D. Yes. Adjustment and discounting were necessary because the authors used DRG charges for hospital costs and therefore they should have used a cost-to-charge ratio.
E. None of the above.
Answer: C. Yes. Adjustment and discounting were necessary but the authors did not conduct it.
Question: What are the strengths and weaknesses of Cost-minimization Analysis?
Answer Options:
A. It measures costs and benefits in dollar terms but difficult to ascribe dollar figure to outcomes.
B. It measures outcomes in clinical terms but difficult to interpret economically.
C. It measures outcomes in life years but hard to estimate quality of life.
D. It is simple to understand because only costs are considered but rarely appropriate to assume equivalent outcomes.
E. None of the above.
Answer: D. It is simple to understand because only costs are considered but it is rarely appropriate to assume that the outcomes are equivalent.
Question: Which drug is considered cost-effective and is the best alternative? (DrugX: $5,000, 20 yrs; DrugY: $3,000, 15 yrs)
Answer Options:
A. DrugX dominates DrugY and therefore is the cost-effective alternative.
B. The cost-effectiveness ratio is $2,000 per life year saved so the answer would depend on whether or not the evaluator believes the extra cost is worth the extra health benefit.
C. DrugX is dominated by DrugY.
D. We cannot determine this from the information given.
Answer: B. The cost-effectiveness ratio is $2,000 per life year saved so the answer would depend on whether or not the evaluator believes the extra cost is worth the extra health benefit.
Question: What type of pharmacoeconomic study is this (Uplift vs fluoxetine, quality of life included)?
Answer Options:
A. Cost-minimization
B. Cost-utility
C. Cost-of-illness
D. Cost-effectiveness
E. None of the above
Answer: B. Cost-utility
Question: Was the title appropriate? Why or why not?
Answer Options:
A. Yes. The title declares what is actually studied.
B. Yes. The title declares the type of study, treatments and provides the perspective of the study.
C. No. The title declares the type of study and treatment but is not specific about the condition studied.
D. No. The title does not declare the type of study or the treatments compared.
E. None of the above.
Answer: C. No. The title declares the type of study and treatment but is not specific about the condition studied.
I will continue formatting the rest of the questions in the same way in the next message to keep it readable.
Continuing from the previous message:
Question: What type of pharmacoeconomic study is this (comparing asthma drugs, outcomes = FEV1)?
Answer Options:
A. Cost-effectiveness
B. Cost-of-illness
C. Cost-minimization
D. Cost-utility
E. None of the above
Answer: A. Cost-effectiveness
Question: Whose costs would be included in a pharmacoeconomic study conducted from the 3rd-Party Payer perspective?
Answer Options:
A. Societal costs
B. Patient costs
C. Costs paid by the insurance company
D. A and B
E. A and C
Answer: C. Costs paid by the insurance company
Question: Were the important or relevant outcomes measured? (Cost-minimization study, LDL vs mortality)
Answer Options:
A. Yes. LDL reduction is the main clinical outcome of interest in secondary MI. The duration was also appropriate.
B. Yes. The relevant outcomes were measured but the duration of the study (one year) was too long.
C. No. The condition of interest was prevention of secondary MI. LDL is only a surrogate marker.
D. No. The relevant outcomes were not measured – although hospital costs, drug costs and mean LDL reduction were appropriate, HDL cholesterol should also have been included.
Answer: C. No. The condition of interest was prevention of secondary MI. LDL is only a surrogate marker.
Question: Were the important or relevant clinical outcomes measured?
Answer Options:
A. Yes. LDL reduction is the main clinical outcome of interest in secondary MI. The duration was also appropriate.
B. Yes. The relevant outcomes were measured but the duration of the study (one year) was too long.
C. No. The condition of interest was prevention of secondary MI. LDL cholesterol is only a surrogate marker.
D. No. The relevant outcomes were not measured – although hospital costs, drug costs and mean LDL reduction were appropriate, HDL cholesterol should also have been included.
Answer: C. No. The condition of interest was prevention of secondary MI. LDL cholesterol is only a surrogate marker.
Question: Is the type of study stated? Is this study type appropriate?
Answer Options:
A. Yes. The authors clearly state that the study is a cost-minimization analysis and this is the appropriate type of study for this comparison because one of the drugs is an inexpensive generic.
B. No. The authors do not state explicitly the type of study but the methods do appear to be appropriate within the context of the study question because there is an inexpensive generic drug available.
C. No. The authors do not state the type of study and the study does not appear to be appropriate because there is a difference in mean LDL reduction.
D. Yes. The type of study is stated but is not the appropriate study for this comparison because the authors show that there is a difference in effectiveness.
E. None of the above.
Answer: D. Yes. The type of study is stated but is not the appropriate study for this comparison because the authors show that there is a difference in effectiveness.